298: A dilemma in ALS, the first MASH drug, & why gene therapy is hard
The Readout Loud
00:00
Introduction
Exploring the implications of a failed FDA-approved drug for ALS and insights from bioethicist Holly Fernandez-Linch. Also, updates on gene therapies, CAR-T cancer treatments, and the first sanctioned medication for liver disease.
Transcript
Play full episode
